


## PHARMACEUTICAL 2017

## Fibrocell Science Inc. Rank 196 of 292





## PHARMACEUTICAL 2017

## Fibrocell Science Inc. Rank 196 of 292

The relative strengths and weaknesses of Fibrocell Science Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Fibrocell Science Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Fibrocell Science Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is 12%, being 9.6% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	18,028
Cost of Goods Sold	697
Intangible Assets	0
Liabilities, Current	2,987
Liabilities, Non-Current	0
Other Assets	65
Other Compr. Net Income	0
Other Expenses	4,468
Other Liabilities	8,734
Other Net Income	11,415
Other Revenues	355
Property and Equipment	1,489
Research and Development	8,400
Selling, General and Administrative Expense	9,773

Output Variable	Value in 1000 USD
Assets	19,582
Liabilities	11,721
Expenses	23,338
Revenues	355
Stockholders Equity	7,861
Net Income	-11,568
Comprehensive Net Income	-11,568
Economic Capital Ratio	12%

